These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 19664336)
1. [(125)I versus (103)Pd brachytherapy for low risk prostate cancer: a systematic review]. Zhang LL; Ma L; Tian JH; Ren YY; Yang KH Ai Zheng; 2009 Aug; 28(8):872-8. PubMed ID: 19664336 [TBL] [Abstract][Full Text] [Related]
2. I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial. Herstein A; Wallner K; Merrick G; Mitsuyama H; Armstrong J; True L; Cavanagh W; Butler W Cancer J; 2005; 11(5):385-9. PubMed ID: 16259869 [TBL] [Abstract][Full Text] [Related]
3. Patient-reported health-related quality of life for men treated with low-dose-rate prostate brachytherapy as monotherapy with 125-iodine, 103-palladium, or 131-cesium: Results of a prospective phase II study. Blanchard P; Pugh TJ; Swanson DA; Mahmood U; Chen HC; Wang X; Graber WJ; Kudchadker RJ; Bruno T; Feeley T; Frank SJ Brachytherapy; 2018; 17(2):265-276. PubMed ID: 29269207 [TBL] [Abstract][Full Text] [Related]
4. Iodine 125 versus palladium 103 implants for prostate cancer: clinical outcomes and complications. Peschel RE; Colberg JW; Chen Z; Nath R; Wilson LD Cancer J; 2004; 10(3):170-4. PubMed ID: 15285926 [TBL] [Abstract][Full Text] [Related]
5. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials. Ghaly M; Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1288-93. PubMed ID: 12654439 [TBL] [Abstract][Full Text] [Related]
7. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435 [TBL] [Abstract][Full Text] [Related]
8. Isotope selection for patients undergoing prostate brachytherapy. Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561 [TBL] [Abstract][Full Text] [Related]
9. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788 [TBL] [Abstract][Full Text] [Related]
10. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Blasko JC; Grimm PD; Sylsvester JE; Cavanagh W Radiother Oncol; 2000 Dec; 57(3):273-8. PubMed ID: 11104885 [TBL] [Abstract][Full Text] [Related]
11. Argon plasma coagulation for rectal bleeding after prostate brachytherapy. Smith S; Wallner K; Dominitz JA; Han B; True L; Sutlief S; Billingsley K Int J Radiat Oncol Biol Phys; 2001 Nov; 51(3):636-42. PubMed ID: 11597803 [TBL] [Abstract][Full Text] [Related]
12. Combined 3-dimensional conformal radiotherapy and transperineal Pd-103 permanent implantation for patients with intermediate and unfavorable risk prostate cancer. Singh A; Zelefsky MJ; Raben A; Lombardi D; Leibel SA Int J Cancer; 2000 Oct; 90(5):275-80. PubMed ID: 11091351 [TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111 [TBL] [Abstract][Full Text] [Related]
14. Radiation safety aspects of brachytherapy for prostate cancer using permanently implanted sources. A report of ICRP Publication 98. International Commission on Radiological Protection Ann ICRP; 2005; 35(3):iii-vi, 3-50. PubMed ID: 16330284 [TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. Kang SK; Chou RH; Dodge RK; Clough RW; Kang HS; Hahn CA; Whitehurst AW; Buckley NJ; Kim JH; Joyner RE; Montana GS; Ingram SS; Anscher MS Int J Radiat Oncol Biol Phys; 2002 May; 53(1):99-103. PubMed ID: 12007947 [TBL] [Abstract][Full Text] [Related]
17. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Merrick GS; Butler WM; Wallner K; Galbreath RW; Anderson RL; Kurko BS; Lief JH Urology; 2002 Jul; 60(1):104-8. PubMed ID: 12100933 [TBL] [Abstract][Full Text] [Related]
18. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants. Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216 [TBL] [Abstract][Full Text] [Related]
19. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Kollmeier MA; Stock RG; Stone N Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768 [TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer. Forsythe K; Blacksburg S; Stone N; Stock RG Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]